783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS)

20225 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 33, pp. S899-S899

Field-Weighted Citation Impact: 0.29